文献速递免疫规划卫生政策与健康促进

香港引入轮状病毒疫苗的经济学评价

Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
PubMed 文献 · Vaccine · 2020-11-18

本研究采用决策支持模型评估香港儿童免疫规划引入轮状病毒疫苗的成本效益,比较Rotarix®两剂与RotaTeq®三剂方案与不接种方案在2020-2029年的影响。结果显示接种可预防大量住院且成本节约概率高,获益风险比约1000:1,支持纳入儿童免疫规划。

要点

  • 轮状病毒疫苗接种在香港可能节约成本且获益风险比良好。
  • 模型预测2020-2029年可预防约49,000例轮状病毒胃肠炎和惊厥住院。
  • 接种相关肠套叠住院约50例,获益风险比约1000:1。

核心结论

  • 轮状病毒疫苗接种在香港可能节约成本并具有有利的获益风险特征,分析支持将其纳入儿童免疫规划。

研究设计与样本

  • 采用定制决策支持模型,评估香港5岁以下儿童2020-2029年接种轮状病毒疫苗的影响、成本效益和获益风险。
  • 比较Rotarix®两剂和RotaTeq®三剂分别与不接种,从政府卫生部门和整体卫生部门视角计算轮状病毒治疗成本。
  • 进行了概率和确定性不确定性分析。

主要发现

  • 与无公私营部门疫苗使用相比,接种可预防49,000(95%不确定性区间:约44,000-54,000)例轮状病毒胃肠炎和惊厥住院。
  • 可能导致约50(95%不确定性区间:约25-85)例肠套叠住院,获益风险比约1000:1。
  • 无论疫苗产品或视角,疫苗具有成本节约的概率大于94%;所有确定性“假设”情景从整体卫生部门视角均成本节约。

临床怎么用

  • 为香港将轮状病毒疫苗纳入儿童免疫规划提供经济学证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotavirus is a common cause of severe gastroenteritis in young children in Hong Kong (HK) with a high economic burden. This study aimed to evaluate the cost-effectiveness of introducing rotavirus vaccination into the HK Government's Childhood Immunisation Programme (CIP) and to include the potential protective effect of the vaccine against seizures. METHODS: A decision-support model was customised to estimate the potential impact, cost-effectiveness and benefit-risk of rotavirus vaccination in children below 5 years over the period 2020-2029 in HK. Two doses of Rotarix® and three doses of RotaTeq® were each compared to no vaccination. Rotavirus treatment costs were calculated from a governmental health sector perspective (i.e., costs of public sector treatment) and an overall health sector perspective (both governmental and patient, i.e., costs of public sector treatment, private sector treatment, transport and diapers). We ran probabilistic and deterministic uncertainty analyses. RESULTS: Introduction of rotavirus vaccination in HK could prevent 49,000 (95% uncertainty interval: ~44,000-54,000) hospitalisations of rotavirus gastroenteritis and seizures and result in ~50 (95% uncertainty interval: ~25-85) intussusception hospitalisations, over the period 2020-2029 (a benefit-risk ratio of ~1000:1), compared to a scenario with no public or private sector vaccine use. The discounted vaccination cost would be US$51-57 million over the period 2020-2029 based on per-course prices of US$72 (Rotarix®) or US$78 (RotaTeq®), but this would be offset by discounted treatment cost savings of US$70 million (government) and US$127 million (governmental and patient health sector). There was a greater than 94% probability that the vaccine could be cost-saving irrespective of the vaccine product or perspective considered. All deterministic 'what-if' scenarios were cost-saving from an overall health sector perspective (governmental and patient). CONCLUSIONS: Rotavirus vaccination is likely to be cost-saving and have a favourable benefit-risk profile in HK. Based on the assumptions made, our analysis supports its introduction into CIP.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yeung KHT, Lin SL, Clark A, et al. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. Vaccine. 2020. PMID: 33221066. doi:10.1016/j.vaccine.2020.10.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。